Overall, it was not a good week for poor Suda Pharmaceuticals (ASX:SUD).
The mouth spray biotech dropped 33 per cent on Tuesday after the Australian Therapeutic Goods Administration declined the company’s appeal to have its anti-malaria mouth spray approved.
Suda still has “more irons in the fire than a gold rush era blacksmith”, says columnist Tim Boreham.
But while it shows far more promise than its penny-dreadful status – and $14 million market capitalisation – would suggest, at this stage it’s hard to glean a holistic picture of likely long-term revenues and profits.
“And quite frankly, unexplained and abrupt CEO departures are unsettling,” Boreham writes.
+$1.2bn market cap Clinuvel (ASX:CUV) isn’t a small cap by any stretch, but you loved this story anyway.
It’s an unusual day in recent trading when shares in biotech stock Clinuvel haven’t risen or fallen by anywhere between 2 to 4 per cent. That’s probably because there’s a decision due October 8 from the Food and Drug Administration (FDA) — the gatekeeper for Clinuvel to gain access to the critical US market.
Broker Moelis says the FDA’s decision remains a “key catalyst” for Clinuvel shares.
Few Australian goldfields have offered more promise than Norseman in WA, but it’s equally true to say that few goldfields have proved more difficult to tame, writes Treadgold.
That’s probably why there hasn’t been a more enthusiastic reaction by investors to Pantoro’s (ASX:PNR) Norseman adventure.
Whatever the challenges at Norseman, Pantoro has one enormous advantage that eluded earlier owners – a local gold price of more than $2,100/oz, four times higher than the $500/oz when WMC sold in 2002.
Yes, this is paid content, but it’s here because you guys loved it so much.
Probably because we asked Steve Parsons — aka managing director at gold darling Bellevue Resources (ASX:BGL) — why he’s increasing his personal stake in Swedish gold and base metals explorer Alicanto Minerals (ASX:AQI).
Stockhead has compiled a list of the top 100 small caps based on share price returns for the year to June 30. We used a cut-off of $500 million market cap.
There’s some interesting stuff in here – like the fact there’s just two resources stocks in the top 10. Have a dig.
In this latest episode stock analysis veteran and lover of the oil and gas game, Peter Strachan, interviews Ansila Energy (ASX:PVD) technical director, Chris Lewis.
Tune in to hear Peter and Chris discuss the Polish gas game, Europe’s desire for energy independence and the ups and downs of natural fractures.
We’re out. See you next week.
share
Link copied to clipboard
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.